BÜHLMANN Calprotectin Assay Citations – Page 5 – Buhlmann Diagnostics Corp

Category: BÜHLMANN Calprotectin Assay Citations

A number of the publications in the citation list describe applications that are outside of product claims thus they should be used for information only.

FOCUS: Future of Fecal Calprotectin Utility Study in Inflammatory Bowel Disease

BÜHLMANN Quantum Blue® fCAL Citation: Rosenfeld G, Greenup A-J, Round A, et al. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. World Journal of Gastroenterology. 2016;22(36):8211-8218. doi:10.3748/wjg.v22.i36.8211. PMID:27688663. Highlight from this Publication "The FC test effected a change in management 51.3% of the time and receipt of the result was associated with a reduction
Continue Reading

A Novel Turbidimetric Immunoassay for Fecal Calprotectin Optimized for Routine Chemistry Analyzers

BÜHLMANN fCAL® turbo Citation: Nilsen, T. et. al.  A novel turbidimetric immunoassay for fecal calprotectin optimized for routine chemistry analyzers. J Clin Lab Anal. 2016 Sep 15. PMID:27629827 The publication describes the technical performance of the turbidimetric assay on the cobas c501 and the Mindray BS-380. Highlight from this Publication Short assay time of 10 min with
Continue Reading

Fecal Calprotectin in Healthy Children Aged 1-4 Years

BÜHLMANN fCAL® ELISA Citation: Zhu, Q,Feng Li, Junli Wang, Lixiao Shen, Xiaoyang Sheng. Fecal Calprotectin in Healthy Children Aged 1-4 Years, PLOS ONE. 2016. http://dx.doi.org/10.1371/journal.pone.0150725.

Highlight from this Publication:

“Children aged from 1 to 4 years old have lower FC concentrations compared with healthy infants (<1years), and higher FC concentrations when comparing with children older than 4 years and adults.”
Continue Reading

Comparison of Three Tests for Faecal Calprotectin in Children and Young Adults: a Retrospective Monocentric Study

BÜHLMANN fCAL® ELISA Citation: Prell, C, Nagel D, Freudenberg H, Schwarzer A, Koletzko S. Comparison of three tests for faecal calprotectin in children and young adults: a retrospective monocentric study, BMJ Open. 2014;4:e004558 doi:10.1136/bmjopen-2013-004558.

Highlights from this Publication

“In conclusion, measurement of FC in paediatric patients with unspecific symptoms is very helpful in order to avoid invasive procedure.”
Continue Reading

Are We Exposing Patients with a Mildly Elevated Faecal Calprotectin to Unnecessary Investigations?

BÜHLMANN fCAL®ELISA Citation: Seenan, JP, Thomson, Rankin K, Smith K, Gaya DR. Are we exposing patients with a mildly elevated faecal calprotectin to unnecessary investigations? Gastroenterology. 2014 Frontline Gastroenterol doi:10.1136/flgastro-2014-100467.

Highlight from this Publication:

“...we propose an alternative diagnostic approach of repeating the FC after 6-8 weeks in patients with values of 100-200 µg/g.”
Continue Reading

Fecal Calprotectin in Inflammatory Bowel Disease

BÜHLMANN fCAL® ELISA Citation Walsham and Sherwood. Fecal calprotectin in inflammatory bowel disease, Clinical and Experimental Gastroenterology. 2016; 9: 21–29.Published online 2016 Jan 28. doi: 10.2147/CEG.S51902

Highlight from this Publication

“The choice of a cutoff will depend on whether sensitivity or specificity is considered to be the most important and needs to be made taking into consideration the clinical features of an individual patient.”
Continue Reading

Diagnostic Accuracy and Clinical Application of Faecal Calprotectin in Adult Patients Presenting with Gastrointestinal Symptoms in Primary Care

BÜHLMANN fCAL®ELISA Citation Pavlidis, P ,Pavlidis P, Chedgy FJ, Tibble JA. Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care, Scandinavian Journal of Gastroenterology. 2013 Sep;48(9):1048-54. doi: 10.3109/00365521.2013.816771.

Highlight from this Publication

“This study provides the first evidence on the use of fCal [BÜHLMANN fCAL® ELISA]testing in primary care…..to be used as part of the pathway for management of patients with suspected IBS.”
Continue Reading

Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy.

Quantum Blue® fCAL Citation: Ferreiro-Iglesias, R. Barreiro-de Acosta M, Otero Santiago M, Lorenzo Gonzalez A, Alonso de la Peña C, Benitez Estevez AJ, Dominguez-Muñoz JE., Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy. J Clin Gastroenterol. 2016 Feb;50(2):147-51. doi: 10.1097/MCG.0000000000000312. Highlight from this Publication “We found FC to
Continue Reading

Fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis

BÜHLMANN fCAL® ELISA Citation Theede, K. ,Holck S, Ibsen P, Kallemose T, Nordgaard-Lassen I, Nielsen AM. Fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis, Inflamm Bowel Dis. 2016 May;22(5):1042-8. doi: 10.1097/MIB.0000000000000736. Highlights from this Publication “…our histological inflammatory activity score is closely related to the concentration of FC and thereby has the advantage
Continue Reading

Comparison of the Liaison® Calprotectin Kit with a Well-Established Point of Care Test (Quantum Blue — Bühlmann-Alere®) in Terms of Analytical Performances and Ability to Detect Relapses Amongst a Crohn Population in Follow-up

Quantum Blue®  fCAL Citation: Delefortrie, Q. Schatt P, Grimmelprez A, Gohy P, Deltour D, Collard G, Vankerkhoven P. Comparison of the Liaison® Calprotectin kit with a well-established point of care test (Quantum Blue — Bühlmann-Alere®) in terms of analytical performances and ability to detect relapses amongst a Crohn population in follow-up, Clinical Biochemistry. 2016 Feb;49(3):268-73. doi: 10.1016/j.clinbiochem.2015.10.010
Continue Reading